Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dasiglucagon in the Inreda bihormonal artificial pancreas feasibility study
NL-OMON57833Phase 2Not yet recruiting
- Sponsor
- Inreda Diabetic
- Start
- May 2022
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of dasiglucagon and glucagon in diabetes mellitus type 1 (T1D) (2 arms), sponsored by Inreda Diabetic. Primary endpoint: Time in range. Planned start May 2022; status: not yet recruiting.
02
Drugs
dasiglucagonglucagon
03
Conditions
diabetes mellitus type 1 (T1D)
Beyond the preview
Go deeper on NL-OMON57833.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON57833.